Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): Cost analysis and complications

Keyphrases

• Myelodysplastic Syndrome 100%
• Cost Analysis 100%
• Transfusion Support 100%
• Blood Product Transfusion 100%
• Transfusion 40%
• Blood Products 40%
• Packed Red Blood Cells 30%
• Median Cost 20%
• Random Donor Platelets 20%
• Minneapolis 10%
• Medical Center 10%
• Disease-modifying Therapy 10%
• Secondary AML 10%
• Allogeneic Transplantation 10%
• Baseline Data 10%
• Supportive Care 10%
• Blood Transfusion 10%
• Long-term Support 10%
• Transfusion Requirements 10%
• High Incidence 10%
• Resource Utilization 10%
• Growth Factor Therapy 10%
• Platelet Transfusion 10%
• Resource Cost 10%
• Premedication 10%
• Transfusion Reaction 10%
• Phase Time 10%
• Single Donor Apheresis Platelets 10%
• Special Processing 10%
• Packed Red Blood Cell Transfusion 10%

Medicine and Dentistry

• Cost Benefit Analysis 100%
• Myelodysplastic Syndrome 100%
• Blood Product 100%
• Health Care Cost 60%
• Acute Myelogenous Leukemia 30%
• Platelet 30%
• Erythrocyte 30%
• Secondary Acute Myeloid Leukemia 10%
• Allograft 10%
• Supportive Care 10%
• Blood Transfusion 10%
• Erythrocyte Transfusion 10%
• Thrombocyte Transfusion 10%
• Donor Apheresis 10%
• Blood Transfusion Reaction 10%
• Premedication 10%
• Growth Factor 10%
• Diseases 10%

Immunology and Microbiology

• Blood Product 100%
• Platelet 80%
• Packed Red Blood Cells 80%
• Growth Factor 20%
• Transfusion Reactions 20%
• Blood Transfusion 20%
• Apheresis 20%
• Allograft 20%